HAO1‐ and LDHA‐targeting, and AGXT gene or mRNA addition therapies could theoretically be applied to all PH1 subjects regardless of the AGXT variant they carry, whereas only 24%–37% of PH1 subjects carry the Gly170Arg variant [6]. This evidence concerns the gene LDHA and primary hyperoxaluria type 1.